
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Navatar’s Latest CRM Platform For M&A Helps Investment Banks Leverage Superior Proprietary Intelligence As M&A Deal Activity Increases



